Europe Age-Related Macular Degeneration (AMD) Disease Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029
Market Analysis and Insights
Europe age-related macular degeneration (AMD) disease market is driven by the factors such as, rising geriatric population, increase in the prevalence of age-related macular degeneration (AMD) disease and pipeline products enhance its demand as well as rising investment in research and development leads to the market growth. Currently, healthcare expenditure has increased across developed and emerging countries that is expected to create a competitive advantage for manufacturers to develop new and innovative products.
The prevalence of age-related macular degeneration, is expected to increase in developed countries due to the aging population and rising life expectancy. It is estimated that nearly 60% of patients have severe visual impairment occurring disease shortly after birth. This disease leads to blurring central vision in the patient’s eye. The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. However, the high cost associated with the treatment and procedure as well as stringent government regulations for product approval are expected to hamper the growth for age-related macular degeneration (AMD) disease market.
Europe age-related macular degeneration (AMD) disease market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that Europe age-related macular degeneration (AMD) disease market will grow at a CAGR of 9.4% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Year |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) |
|
Countries Covered |
By Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2029 |
|
Market Players Covered |
Novartis AG, PIXIUM VISION, Bayer AG, Astellas Pharma Inc., Ionis Pharmaceutics, Johnson & Johnson Services, Inc, Gensight Biologics, Kodiak Sciences Inc. among others |
Market Definition
Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Sometimes abnormal new blood vessels grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. Other reasons for the rising of procedures can be defined by the increasing aging people causes and the requirement for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.
The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of the disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth. However, these treatments are expensive and not available to all patients.
Europe Age-Related Macular Degeneration (AMD) Disease Market Dynamics
Drivers
- Rising geriatric population
The world’s geriatric population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in the number of elderly patients due to the rising prevalence of chronic disease. Age is a severe risk factor for any disease progression as age is an essential parameter that affects fundamental biological mechanisms. Therefore, aging is one of the risk factors for the Europe incidence of early AMD. Age-related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.
Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process. Thus, the increasing rate of the geriatric population is expected to drive the growth of the Europe age-related macular degeneration (AMD) disease market growth.
- Increasing Prevalence of Age-Related Macular Degeneration (AMD) Disease
The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. These countries had reimbursement policies for age-related macular degeneration (AMD) disease market along with that increasing prevalence of genetic diseases.
Thus, it signifies that increasing prevalence of age-related macular degeneration (AMD) disease is expected to drive the Europe age-related macular degeneration (AMD) disease market growth.
Opportunity
- Rising Research and Development
Research and development is a prerequisite to modifying the treatment intended to treat different kinds of patients. The demand for age-related macular degeneration (AMD) treatment and procedures increasing worldwide involving every country Europe. This is why the companies are continuously focusing on research and development in order to achieve success in providing effective treatment to patients and healthcare workers.
The effects can be seen only for individuals in certain ways that include effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and suffering permanent damage.
As the companies are constantly engaged in developmental activities more innovative products are launched in the market. This thus signifies that increasing research and development is expected as an opportunity for the Europe age-related macular degeneration (AMD) disease growth. The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the Europe age-related macular degeneration (AMD) disease market.
Restraint/Challenge
- High cost of aesthetic surgical procedures
The cost of the product plays a major factor in the market. In the age-related macular degeneration (AMD) disease, it is generally observed that they are highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.
Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment. But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with age-related macular degeneration (AMD) disease treatment and diagnosis is expected to restrain the Europe age-related macular degeneration (AMD) disease market growth.
Recent Developments
- In January 2022, Genentech, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of wet AMD and DME. This will help the company to commercialize the product in the market in the forecast period.
- In April 2022, Graybug Vision Inc. announced that the company has presented a poster presentation preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting for GB-401 in primary open-angle glaucoma (POAG). This will increase the chances for safety and evaluation of drug in the market.
Europe Age-Related Macular Degeneration (AMD) Disease Market Segmentation
Europe age-related macular degeneration (AMD) disease market is categorized into is categorized into three notable segments which are based on type, end user and distribution channel. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Dry AMD
- Wet AMD
On the basis of type, the Europe age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD.
End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Home Healthcare
- Others
On the basis of end user, the Europe age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others.
Distribution Channel
- Retail Sales
- Direct Tender
On the basis of distribution channel, the Europe age-related macular degeneration (AMD) disease market is segmented into retail sales and direct tender.
Age-related Macular Degeneration (AMD) Disease Market Regional Analysis/Insights
The age-related macular degeneration (AMD) disease market is analysed and market size insights and trends are provided by type, end user and distribution channel as referenced above.
The countries covered in the age-related macular degeneration (AMD) disease report are Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and Rest of Europe.
Germany is expected to dominate due to increasing technological advancement in the developing areas.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Age-Related Macular Degeneration (AMD) Disease Market Share Analysis
Europe age-related macular degeneration (AMD) disease market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on age-related macular degeneration (AMD) disease market.
Some of the players in the market are Novartis AG, PIXIUM VISION, Bayer AG, Astellas Pharma Inc., Ionis Pharmaceutics, Johnson & Johnson Services, Inc, Gensight Biologics, Kodiak Sciences Inc. among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION
6.1.2 INCREASING GERIATRIC POPULATION
6.1.3 INCREASE IN PIPELINE PRODUCTS
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 INCREASING RESEARCH AND DEVELOPMENT
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)
6.4 CHALLENGES
6.4.1 LIMITED ACCESS TO TREATMENT
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS
7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE
7.1 OVERVIEW
7.2 DRY AMD
7.3 WET AMD
7.3.1 MEDICATIONS
7.3.2 ANTI-VEGF THERAPY
7.3.3 GENE THERAPY
7.3.4 SURGERY
8 EUROPE AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CLINICS
8.4 AMBULATORY SURGICAL CENTERS
8.5 HOME HEALTHCARE
8.6 OTHERS
9 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 RETAIL SALES
9.2.1 HOSPITAL PHARMACIES
9.2.2 RETAIL PHARMACIES
9.2.3 OTHERS
9.3 DIRECT TENDER
10 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION
10.1 EUROPE
10.1.1 GERMANY
10.1.2 FRANCE
10.1.3 U.K.
10.1.4 RUSSIA
10.1.5 ITALY
10.1.6 SPAIN
10.1.7 NETHERLANDS
10.1.8 SWITZERLAND
10.1.9 POLAND
10.1.10 TURKEY
10.1.11 AUSTRIA
10.1.12 HUNGARY
10.1.13 NORWAY
10.1.14 IRELAND
10.1.15 LITHUANIA
10.1.16 REST OF EUROPE
11 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: EUROPE
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 NOVARTIS AG
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENT
13.1.5.1 AGREEMENT
13.2 GENENTECH, INC.
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 BAYER AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 ADVERUM BIOTECHNOLOGIES, INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENT
13.5 ASTELLAS PHARMA INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENT
13.6 GRAYBUG VISION INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENT
13.7 GENSIGHT BIOLOGICS
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.7.4.1 EVENT
13.7.4.2 AWARD
13.8 IONIS PHARMACEUTICALS
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.8.4.1 EVENT
13.9 IVERIC BIO
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 JOHNSON &JOHNSON SERVICES, INC.
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.10.4.1 COLLABORATION
13.11 KODIAK SCIENCES INC.
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 MEIRAGTX LIMITED
13.12.1 COMPANY SNAPSHOT
13.12.2 PRODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENTS
13.12.3.1 EVENTS
13.12.3.2 AWARD
13.12.3.3 COLLABORATION
13.13 OCUGEN INC.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.13.3.1 INVESTMENT
13.13.3.2 CLINICAL TRIAL
13.14 PIXIUM VISION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENT
13.14.4.1 AWARD
13.15 REGENXBIO INC.
13.15.1 COMPANY SNAPSHOT
13.15.2 PRODUCT PORTFOLIO
13.15.3 RECENT DEVELOPMENTS
13.15.3.1 EVENT
13.15.3.2 COLLABORATION
13.15.3.3 CERTIFICATION
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION
TABLE 2 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 EUROPE DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 8 EUROPE HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 14 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 16 EUROPE DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 18 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 20 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 21 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 22 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 23 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 GERMANY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 26 GERMANY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 27 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 28 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 29 GERMANY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 30 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 FRANCE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 32 FRANCE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 33 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 34 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 35 FRANCE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 36 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 U.K. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 38 U.K. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 39 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 40 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 41 U.K. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 RUSSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 44 RUSSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 45 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 46 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 47 RUSSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 48 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 ITALY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 50 ITALY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 51 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 52 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 53 ITALY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 54 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SPAIN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 56 SPAIN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 57 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 58 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 59 SPAIN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 60 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 NETHERLANDS WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 62 NETHERLANDS MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 63 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 64 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 65 NETHERLANDS RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 SWITZERLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 68 SWITZERLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 69 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 70 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 71 SWITZERLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 POLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 74 POLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 75 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 76 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 77 POLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 TURKEY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 80 TURKEY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 81 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 82 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 83 TURKEY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 AUSTRIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 86 AUSTRIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 87 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 88 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 89 AUSTRIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 90 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 HUNGARY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 92 HUNGARY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 93 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 94 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 95 HUNGARY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 96 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 NORWAY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 98 NORWAY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 99 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 100 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 101 NORWAY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 102 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 IRELAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 104 IRELAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 105 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 106 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 107 IRELAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 108 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 LITHUANIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 110 LITHUANIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 111 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 112 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 113 LITHUANIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 114 REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 2 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DROC ANALYSIS
FIGURE 4 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRY AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
FIGURE 16 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2021
FIGURE 17 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2021
FIGURE 21 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 22 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 23 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 24 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SNAPSHOT (2021)
FIGURE 29 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021)
FIGURE 30 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 31 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 32 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE (2022-2029)
FIGURE 33 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY SHARE 2021 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
